Can a common heart drug prevent deadly bleeding in liver disease?
NCT ID NCT06861075
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests whether the drug carvedilol can reduce high blood pressure in the liver's blood vessels, a common problem in people with cirrhosis. High pressure raises the risk of life-threatening bleeding. The trial will enroll 30 adults with cirrhosis and use a special ultrasound to measure pressure changes after one month of treatment. The goal is to see if carvedilol can safely lower that pressure enough to prevent bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Estaing Medecine Digestive Et Hepatobiliaire
RECRUITINGClermont-Ferrand, 63003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lise Laclautre
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact
Conditions
Explore the condition pages connected to this study.